The Shu complex prevents mutagenesis and cytotoxicity of single-strand specific alkylation lesions

  1. Braulio Bonilla
  2. Alexander I Brown
  3. Sarah R Hengel
  4. Kyle S Rapchak
  5. Debra Mitchell
  6. Catherine A Pressimone
  7. Adeola A Fagunloye
  8. Thong T Luong
  9. Reagan A Russell
  10. Rudri K Vyas
  11. Tony M Mertz
  12. Hani S Zaher
  13. Nima Mosammaparast
  14. Ewa P Malc
  15. Piotr A Mieczkowski
  16. Steven Roberts  Is a corresponding author
  17. Kara A Bernstein  Is a corresponding author
  1. University of Pittsburgh School of Medicine, United States
  2. Washington State University, United States
  3. Washington University in St Louis, United States
  4. University of North Carolina Chapel Hill, United States

Abstract

Three-methyl cytosine (3meC) are toxic DNA lesions, blocking base pairing. Bacteria and humans, express members of the AlkB enzymes family, which directly remove 3meC. However, other organisms, including budding yeast, lack this class of enzymes. It remains an unanswered evolutionary question as to how yeast repairs 3meC, particularly in single-stranded DNA. The yeast Shu complex, a conserved homologous recombination factor, aids in preventing replication-associated mutagenesis from DNA base damaging agents such as methyl methanesulfonate (MMS). We found that MMS-treated Shu complex-deficient cells, exhibit a genome-wide increase in A:T and G:C substitutions mutations. The G:C substitutions displayed transcriptional and replicational asymmetries consistent with mutations resulting from 3meC. Ectopic expression of a human AlkB homolog in Shu-deficient yeast rescues MMS-induced growth defects and increased mutagenesis. Thus, our work identifies a novel homologous recombination-based mechanism mediated by the Shu complex for coping with alkylation adducts.

Data availability

All unique mutations identified by DNA sequencing are reported in Supplemental Table 3 and all sequencing reads are reported in Supplemental Table 5. Raw sequencing reads in fastq format have been submitted to the NCBI short read archive under BioProject accession number PRJNA694993.

The following data sets were generated

Article and author information

Author details

  1. Braulio Bonilla

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Alexander I Brown

    Molecular Biosciences, Washington State University, Pullman, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Sarah R Hengel

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Kyle S Rapchak

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Debra Mitchell

    Molecular Biosciences, Washington State University, Pullman, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Catherine A Pressimone

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Adeola A Fagunloye

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2383-9469
  8. Thong T Luong

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Reagan A Russell

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Rudri K Vyas

    Molecular Biosciences, Washington State University, Pullman, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Tony M Mertz

    Molecular Biosciences, Washington State University, Pullman, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Hani S Zaher

    Biology, Washington University in St Louis, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7424-3617
  13. Nima Mosammaparast

    Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Ewa P Malc

    Genetics, University of North Carolina Chapel Hill, Chapel Hill, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Piotr A Mieczkowski

    Genetics, University of North Carolina Chapel Hill, Chapel Hill, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Steven Roberts

    Molecular Biosciences, Washington State University, Pullman, United States
    For correspondence
    steven.roberts2@wsu.edu
    Competing interests
    The authors declare that no competing interests exist.
  17. Kara A Bernstein

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    For correspondence
    karab@pitt.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2247-6459

Funding

National Institutes of Health (ES030335)

  • Kara A Bernstein

National Institutes of Health (CA218112)

  • Steven Roberts

American Cancer Society (129182-RSG-16-043-01-DMC)

  • Kara A Bernstein

American Cancer Society (133947-PF-19-132-01-DMC)

  • Sarah R Hengel

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Bonilla et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,321
    views
  • 167
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Braulio Bonilla
  2. Alexander I Brown
  3. Sarah R Hengel
  4. Kyle S Rapchak
  5. Debra Mitchell
  6. Catherine A Pressimone
  7. Adeola A Fagunloye
  8. Thong T Luong
  9. Reagan A Russell
  10. Rudri K Vyas
  11. Tony M Mertz
  12. Hani S Zaher
  13. Nima Mosammaparast
  14. Ewa P Malc
  15. Piotr A Mieczkowski
  16. Steven Roberts
  17. Kara A Bernstein
(2021)
The Shu complex prevents mutagenesis and cytotoxicity of single-strand specific alkylation lesions
eLife 10:e68080.
https://doi.org/10.7554/eLife.68080

Share this article

https://doi.org/10.7554/eLife.68080

Further reading

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Senem Ntourmas, Martin Sachs ... Dominic B Bernkopf
    Research Article

    Activation of the Wnt/β-catenin pathway crucially depends on the polymerization of dishevelled 2 (DVL2) into biomolecular condensates. However, given the low affinity of known DVL2 self-interaction sites and its low cellular concentration, it is unclear how polymers can form. Here, we detect oligomeric DVL2 complexes at endogenous protein levels in human cell lines, using a biochemical ultracentrifugation assay. We identify a low-complexity region (LCR4) in the C-terminus whose deletion and fusion decreased and increased the complexes, respectively. Notably, LCR4-induced complexes correlated with the formation of microscopically visible multimeric condensates. Adjacent to LCR4, we mapped a conserved domain (CD2) promoting condensates only. Molecularly, LCR4 and CD2 mediated DVL2 self-interaction via aggregating residues and phenylalanine stickers, respectively. Point mutations inactivating these interaction sites impaired Wnt pathway activation by DVL2. Our study discovers DVL2 complexes with functional importance for Wnt/β-catenin signaling. Moreover, we provide evidence that DVL2 condensates form in two steps by pre-oligomerization via high-affinity interaction sites, such as LCR4, and subsequent condensation via low-affinity interaction sites, such as CD2.

    1. Biochemistry and Chemical Biology
    Bikash Adhikari, Katharina Schneider ... Elmar Wolf
    Research Article

    The development of proteolysis targeting chimeras (PROTACs), which induce the degradation of target proteins by bringing them into proximity with cellular E3 ubiquitin ligases, has revolutionized drug development. While the human genome encodes more than 600 different E3 ligases, current PROTACs use only a handful of them, drastically limiting their full potential. Furthermore, many PROTAC development campaigns fail because the selected E3 ligase candidates are unable to induce degradation of the particular target of interest. As more and more ligands for novel E3 ligases are discovered, the chemical effort to identify the best E3 ligase for a given target is exploding. Therefore, a genetic system to identify degradation-causing E3 ligases and suitable target/E3 ligase pairs is urgently needed. Here, we used the well-established dimerization of the FKBP12 protein and FRB domain by rapamycin to bring the target protein WDR5 into proximity with candidate E3 ligases. Strikingly, this rapamycin-induced proximity assay (RiPA) revealed that VHL, but not Cereblon, is able to induce WDR5 degradation - a finding previously made by PROTACs, demonstrating its predictive power. By optimizing the steric arrangement of all components and fusing the target protein with a minimal luciferase, RiPA can identify the ideal E3 for any target protein of interest in living cells, significantly reducing and focusing the chemical effort in the early stages of PROTAC development.